Intervention: Benzoic acid, 3-((S)-(4-((4-acetyl-3-hydroxy-2-propylphenoxy)methyl)phenyl)hydroxymethyl)-
Trial phase: Phase 2
SMILES: CCCc1c(OCc2ccc(C(O)c3cccc(C(=O)O)c3)cc2)ccc(C(C)=O)c1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 41
Group description: 300 milligrams (mg) administered orally as two 150-mg capsules, once daily, for 12 weeks.
Eligibility criteria:
Inclusion Criteria:

Are migraine patients with migraine onset before 50 years of age
Present with diagnosis of at least 1 year with migraine attack defined by International Headache Society (IHS) guidelines
Have a frequency of 4 to 14 migraine attacks, with or without aura, per month (with no more than 14 headache days per month, migraine or non-migraine) for at least the last 6 months
Female patients of childbearing potential must test negative for pregnancy at the time of enrollment and agree to use a reliable method of birth control during the study

Exclusion Criteria:

Are currently enrolled in, or discontinued within the previous 6 months from a migraine clinical trial involving an investigational drug or device or off-label use of a drug or device
Are currently enrolled in, or discontinued within the previous 30 days from screening from a non-migraine clinical trial involving an investigational drug or device or off-label use of a drug or device, or concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
Have previously completed or withdrawn from this study or any other study investigating LY2300559
Have known allergies to LY2300559 or related compounds (such as montelukast)
Are under treatment with medication or procedures for prevention of migraine, or are taking any other medications that are excluded by the protocol
Have a history of alcohol or drug abuse/dependence within the past 3 months of screening or are currently using alcohol, drugs of abuse (including opioids, barbiturates, and marijuana), or any prescribed or over-the-counter medication in a manner that the investigator considers indicative of abuse/dependence
Screen positive for drugs of abuse
Patients with medication overuse headache as per IHS definition
Have a body mass index (BMI) of less than 18.5 or greater than or equal to 35.0
Have history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, constituting a risk when taking the study medication or interfering with the interpretation of the data
Show evidence of serious active neuropsychiatric disease including, but not limited to, bipolar disorder, schizophrenia, psychosis, cluster B personality disorders [for example (eg), borderline personality disorder or narcissistic personality disorder], obsessive-compulsive disorder, or other serious mood, anxiety, depression, or substance/alcohol use disorders
Have ever in his/her lifetime attempted suicide, have any recent suicidal ideation within the last 3 months, or are at significant risk to commit suicide, as judged by the investigator
Show evidence or have history of neurological disease such as cerebral vascular accident, pseudotumor cerebri, multiple sclerosis, transient ischemic attack, syncopal episodes, encephalitis, or meningitis
Have a history or seizures other than febrile
Female patients who are pregnant or breast-feeding
Females of childbearing potential who are not using a clinically acceptable method of birth control (eg, oral contraceptives or abstinence)
Are unwilling or unable to comply with the use of a data collection device to directly record patient data
Are otherwise unable to comply with the requirements of the study